Boryung Biopharma Co., Ltd.

Quick facts

Phase 3 pipeline

• BR-TD-1001 · Neurology
  BR-TD-1001 is a dual-acting compound that modulates both TrkA and p75NTR signaling pathways involved in neuroinflammation and neurodegeneration.
• DTaP-IPV combination vaccine · Immunology
  This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.
• Td-pur inj · Oncology
  Td-pur is an immunotherapeutic injection designed to stimulate anti-tumor immune responses through a purified tumor-associated antigen or dendritic cell-based approach.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Boryung Biopharma Co., Ltd. portfolio CI brief
• Boryung Biopharma Co., Ltd. pipeline updates RSS